SunRegen Healthcare was announced as the winner of the BIO-Europe® 2018 Startup Slam competition, held in Copenhagen. Dr Yuhong Dong, Director and co-founder of SunRegen pre sented on how the company’s therapeutic is a potentially transformative healthcare solution for neurodegenerative eye diseases. More details is published in PR Newwire.
SunRegen attracted the eyes of investors and won strong support from industry and academia scientists. On the first anniversary, SunRegen closed its seed round financing to move ahead the promising project for the treatment of neurological disorders.
In August, SunRegen founder team present its project in the CTI coaching acceptance meeting. The jury acknowledged the potent potential value in the neurodegenerative disorders’ market and showed green light. Swiss CTI will continue to support SunRegen and offered the
professional coaching to be executed by Dr. Andreas J. Schulze.
In order to encourage the research collaboration with Swiss research groups, CTI granted innovation cheque for SunRegen to collaborate with the Brain Mind Institute (BMI) in École polytechnique fédérale de Lausanne (EPFL). The collaboration with EPFL will greatly expend the research capability expend the research capability expend the research capabilityof SunRegen.
SunRegen SBC003 project was accepted as a phase I project by BaseLaunch, which is a healthcare accelerator backed by Novartis, Pfizer, Johnson & Johnson, and Roche. (please visit BaseLaunch portfolio.).
After thorough check upon SunRegen’s business idea, Swiss Commission for Technology and Innovation (CTI) decided to offer CTI coaching phase 2 to SunRegen. CTI coach Dr. Andreas J. Schulze will do professional evaluation for SunRegen business concept.